Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adults
NCT05426174Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mRNA NA vaccine in influenza (4 arms), sponsored by Sanofi. Primary endpoints: Number of participants with immediate adverse events, Number of participants with solicited injection site or systemic reaction and 4 more. Started Jun 2022; status: completed.
02
Drugs
mRNA NA vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05426174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05426174.